Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane

Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane

Abstract Background Dexrazoxane has been studied for its ability to prevent anthracycline-induced cardiac dysfunction (AICD) in several trials but its use in clinical practice remains limited. This is related to the low to moderate quality of the generated evidence, safety concerns and restricted pr...

Full description

Saved in:
Bibliographic Details
Main Authors: Marijke Linschoten, Jesse Geels, Erik van Werkhoven, Heleen Visser-Wisselaar, Martine E. D. Chamuleau, Arco J. Teske, Lourens Robbers, Simone Oerlemans, Heleen Crommelin, Marleen Breems-de Ridder, Astrid Schut, Folkert W. Asselbergs, Anna van Rhenen, on behalf of the HOVON 170 DLBCL – ANTICIPATE consortium
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Cardio-Oncology
Subjects:
Diffuse large B-Cell lymphoma
R-CHOP chemotherapy
Anthracyclines
Dexrazoxane
Cardiotoxicity
Randomized Controlled Trial
Online Access:https://doi.org/10.1186/s40959-025-00303-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40959-025-00303-y

Similar Items